메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Fullerton Health Announces Strategic Investment by Mitsubishi Corporation

SINGAPORE, Aug. 26, 2025 -- Fullerton Health Pte. Ltd. ("Fullerton Health" or the "Company"), a leading healthcare solutions provider operating in nine markets across Asia-Pacific, today announced that Mitsubishi Corporation has acquired a strategic minority stake in the Company. This partnership marks a significant milestone in Fullerton Health's growth journey, enabling greater shareholder alignment as the Company sharpens its focus on regional growth and accelerates its vision for integrated, digitally enabled care and service. This investme
- 김갑성 기자
- 2025-08-26 10:00
MORROW founder invests US $156m and launches new flagship in Singapore as US $8 trillion longevity revolution ramps up

SINGAPORE, Aug. 26, 2025 -- Entrepreneur Allen Law is to open MORROW, a 38,000 sq ft centre that empowers individuals to adopt a healthy lifestyle with a personalised roadmap, supported by a team of professionals and coaches, as part of his global mission to increase the human healthspan. US $156m (SGD $200m) will be invested in opening MORROW locations over the next five years, with US $15.6M (SGD $20m) invested in the initial set-up and technology of an initial flagship in Singapore, which will be located inside the 80,000 sq ft Longevity World at 10 Coleman Street. T
- 김갑성 기자
- 2025-08-26 08:00
Angelalign Technology Announces First-Half 2025 Results While Increasing Investments in Legal, Supply Chain and Data Security

SAN CLEMENTE, Calif., Aug. 26, 2025 -- Angelalign Technology Inc. ("Angel" or the "Company") (6699.HK) announced its interim results for the first half of 2025. The Company delivered solid performance for the first six months of the year. In the first half of 2025, Angel reported a year-over-year revenue increase of 33.1% to US$161.4 million, with gross profit of US$100.6 million and adjusted net profit of US$19.5 million. Global clear aligner case volume grew 47.7% year-over-year to approximately 225,800 cases. The growth in case shipments, a
- 김갑성 기자
- 2025-08-26 07:28
모로우 창립자, 8조달러 규모 장수 혁명 가속화 속 1억5600만달러 투자...싱가포르에 첫 플래그십 센터 오픈

싱가포르, 2025년 8월 26일 -- 기업가 앨런 로우(Allen Law)가 인간 건강수명 연장이라는 글로벌 미션의 일환으로 개인이 전문가와 코치의 도움으로 맞춤형 로드맵을 통해 건강한 생활 방식을 채택할 수 있도록 지원하는 3500제곱미터 규모의 모로우(MORROW) 센터를 오픈한다. 향후 5년간 1억5600만달러를 투자해 다수의 모로우 지점을 오픈할 계획이며, 이 중 1560만달러는 싱가포르에 위치한 첫 번째 플래그십 센터의 초기 설비 및 기술 개발에 투입된다. 이 플래그십 센터는 콜먼 스트리트 10번지에 위치한 7400제곱미터 규모의 롱제비티 월드(Longevity World) 내에 들어설 예정이다. 모로우의 출범은 전 세계가 인간 삶의 모든 양상을 변화시킬 잠재력을 지닌 8조달러 규모의 장수 혁명[1]을 시작하는 시점에 기념비적인 순간을 상징한다. 2025년 3월 UBS는 '장수'가 AI와 함께 향후 10년간 주식 시장을 주도할 가장 중요한 혁신 기회 중 하나가 될 것이라고 단언했다. 모로우는 초고소득층을 겨냥한 기존 모델에서 벗어나 훨씬 더 넓은 고객층에 고품질 서비스를 제공하는 것을 목표로
- 황정호 기자
- 2025-08-26 07:00
Infinitus Named in Liaowang Institution's "Leading Transparent Factory Case Studies"

GUANGZHOU, China, Aug. 26, 2025 -- Amid the digital economy and shifting consumer expectations, "trust" has become a core driver of sustainable business growth. The "Transparent Factory • Building the Future with Trust — 2025 Trust Productivity High-End Dialogue" was held in Jiangmen, Guangdong from August 19-20, 2025. During the event, Xinhua News Agency's national high-end think tank, Liaowang Institution, released a report titled "Digital Intelligence Driving • Value Enhancement: Leading Transparent Factory Case Studies" (the "Report"). Infinitus (Ch
- 김갑성 기자
- 2025-08-26 02:55
Neopharma Technologies and Orient Gene Partner to Digitize Healgen® Drug Test Portfolio Globally with NEOVAULT®

Partnership delivers tamper-evident, high-integrity testing data aligned with U.S. Drug Policy Priorities WASHINGTON, Aug. 26, 2025 -- Neopharma Technologies Limited ("Neopharma") today announced it has entered into a global software licensing and collaboration agreement with Zhejiang Orient Gene Biotech Co., Ltd. ("Orient Gene") to integrate Neopharma's NEOVAULT® software across Orient Gene's range of Drugs of Abuse (DOA) rapid tests under the Healgen® brand. Why This Matters The partnership combines proven rapid drug tes
- 김갑성 기자
- 2025-08-26 02:10
Everest Medicines Announces Participation in September Investor Conferences

SHANGHAI, Aug. 25, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer will be participating in person at investor conferences in New York City. Morgan Stanley 23rd Annual Global Healthcare Conference Date: Monday September 8, 2025 Format: Fireside chat and 1x1 meetings Time: 5:35 p.m. ET Location: New York, NY&nbs
- 김갑성 기자
- 2025-08-25 20:57
Peijia Medical Announces 2025 Interim Results

HONG KONG, Aug. 25, 2025 -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months ended June 30, 2025 ("the Reporting Period") on August 22, 2025. The Group reported sustained revenue growth and significantly improved expense ratios, driving a structural enhancement in profitability. Revenue reached RMB353.4 million, up 17.3% period-to-period. Revenue composition remained stable, with TAVR-related products and
- 김갑성 기자
- 2025-08-25 20:00
Acceleration in Clinical Development! Leads Biolabs' LBL-034 Dosed First Patient in Phase Ⅱ Trial

NANJING, China, Aug. 25, 2025 -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following strong Phase Ⅰ data. This milestone endows LBL-034 with the potential to become the first domestic T-cell engager (TCE) therapy targeting GPRC5D. Innovative Design with Best-in-Class Potential LBL-034 is a GPRC5D/CD3 bispecific T-cell engager with a uniquely designed 2:1 format. By optimizing anti-CD3 affinity and steric
- 김갑성 기자
- 2025-08-25 18:27
Pulnovo Medical Names Dr. Francis Duhay as Global Chief Medical Officer

SHANGHAI, Aug. 25, 2025 -- Pulnovo Medical, a global leader in mechanism-driven therapies for Pulmonary Hypertension (PH) and Heart Failure (HF), today announced the appointment of Francis Duhay, MD, MBA, FACS as Global Chief Medical Officer. Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership. As former Chief Medical Officer at Edwards Lifesciences (NYSE: EW), he played a decisive role in the development, clinical validation, and worldwide adoption of Transcatheter
- 김갑성 기자
- 2025-08-25 16:42

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-09-04_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 12시 20분